Eunoia Biotech is committed to winning the war on diseases. Using our proprietary technology, we create new and innovative investigational treatments, forging a shift in paradigm for traditional disease treatments options. At Eunoia, we use a collaborative approach and state of the art technologies on our quest to research and develop new treatments for diseases.
Eunoia Biotech is a preclinical-stage drug delivery company, established in September 2013 and located in the state of the art research facility at Lankenau Institute for Medical Research, just outside Philadelphia. We are focused on building a strong corporate culture around the values of integrity, scientific excellence, innovation, teamwork and mutual respect. Eunoia Biotech embodies an entrepreneurial spirit that advances breakthrough technologies by innovating and building from the ground up.
Meet the Team
Kenny Roberts, PhD
Founder and Chief Executive Officer
Kenny Roberts serves as our Chief Executive Officer since our inception in 2013. Prior to founding Eunoia, Dr. Roberts was employed by Harvard University’s Wyss Institute for Biologically Inspired Engineering as a Staff Scientist, Advance Technology, where he was responsible for designing multifunctional biomaterials for tissue regeneration and pursuing innovative technologies for drug delivery. Prior to Harvard, Dr. Roberts worked as a Research Scientist at Centocor (Johnson & Johnson) as a Research Scientist in PK/PD and Evaluation Half-life Extension Technologies and Pulmonary Drug Delivery. Prior to Centocor, Dr. Roberts worked as a Research Associate at Duke University in Stimuli-reponsive polymers for tissues regeneration and Drug Delivery. Dr. Roberts holds a B.S. in Chemistry from the University of Wales, Bangor and holds a PhD in Chemistry from the State University of New York at Stony Brook.
Eugene Cooper, PhD
Eugene Cooper serves as an advisor to Eunoia. Dr. Cooper has over 30 years of experience in industrial research and development. Prior to advising Eunoia, Dr. Cooper held lead positions at QR Pharma, SoluBest Ltd., Sterling Winthrop, Alcon, Proctor & Gamble, Quadrant Drug Delivery Limited (Elan Corp. and Elan Drug Delivery). Dr. Cooper is a member of the Scientific Advisory Board of iCeutica, Inc. since 2005. Dr. Cooper won a National Science Foundation Postdoctoral Fellowship in Chemistry. He is the Author of numerous research articles and patents. He is the recipient of the top prize in Pharmaceutical Sciences, The Ebert Prize and in 1993, received the President’s Award for the most significant contribution to all of Sterling Winthrop, the invention of NanoCrystal technology. His undergraduate training was in Mathematics and Physics. He has attended the Harvard Business School Program for Management Development. He holds a PhD in Theoretical Physical Chemistry from Iowa State University.
Eduardo Nieto serves as a member of our advisory board. Mr. Nieto is the President and Founder of Electio Consulting. He also is a Partner and Founder of Progalenika. Mr. Nieto is a lead marketing expert with over 28 years of experience. Mr. Nieto held lead positions including Vice President of Marketing Latin America at Glaxo SmithKline and President Latin America at Wyeth Pharmaceuticals. Mr. Nieto studied Business Administration, Finance and Marketing at the Universidad Panamericana. He has attended the Wharton School of the University of Pennsylvania’s Corporate Governance Program.
Samir Parikh, MD
Samir Parikh serves as our collaborator (member). Dr. Parikh is a Professor at Harvard Medical School. He is a staff physician at Beth Israel Medical Center in the Division of Nephrology and a principal investigator with joint affiliations in the Division of Nephrology and the Center for Vascular Biology Research. Dr. Parikh holds a B.S. in Chemistry from Harvard University. Dr. Parikh holds a MD from Vanderbilt University School of Medicine. He completed post-graduate medical training at Beth Israel Deaconess Medical Center and Harvard Medical School, including a research fellowship with Vikas Sukhatme. His research interest is Vascular Dysfunction in Sepsis.
J. Andrew MacKay, PhD
J. Andrew MacKay serves as our collaborator (member). Dr. MacKay is a Professor at the University of Southern California. He holds a SB in Chemical Engineering and Biology from the Massachusetts Institute of Technology. After working for a Boston area biotechnology company, he entered the Joint Graduate Group in Bioengineering at the University of California at San Francisco and Berkeley, where he earned a Howard Hughes Medical Institute Predoctoral Fellowship. As a postdoctoral researcher at Duke University, he earned a Kirshstein National Research Service Award Postdoctoral Fellowship. He is on the faculty at the University of Southern California in the Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy; the Department of Biomedical Engineering, Viterbi School of Engineering; and, the Department of Ophthalmology, Keck School of Medicine. Dr. MacKay’s research interests are in protein polymers and liposomes.